THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL

Universitas Sriwijaya

Status and phase: Completed; Phase 3

Conditions: COVID-19

Treatments: Dietary Supplement: Neomune

Study type: Interventional

Funder types: Other

Identifiers

NCT06004375

ID

Details and patient eligibility

About

The goal of this clinical trial is to determine effect of arginine and glutamine on outcome of COVID-19 patients. The main questions it aims to answer are:

-to test the effect of oral nutritional supplements containing arginine and glutamine on covid-19 patients outcome Dr. M. Djamil General Hospital Padang

Participants will given ONS containing arginine and glutamine. Researchers will compare intervention group with control group to see if ONS affected outcome of COVID-19 patients

Enrollment: 20 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients confirmed positive for COVID-19
• Age over 17 years
• The patient can take food orally

Exclusion criteria

• Patients with restricted fluid intake
• Patients who cannot take food orally
• suffering from diabetes mellitus and kidney failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

20 participants in 2 patient groups

intervention group

Experimental group

Description:

The intervention group was given a High-Calorie High-Protein + ONS diet containing 4.8 g arginine and 2 g glutamine, namely Neomune 2x 200 cc, purchased from Otsuka Pharmaceutical Co., Ltd

Treatment:

Dietary Supplement: Neomune

control group

Active Comparator group

Description:

the control was administered with a High-Calorie High-Protein diet + ONS hospital standard.

Treatment:

Dietary Supplement: Neomune